{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T22:21:22Z","timestamp":1770157282116,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleotropic-glycoprotein (P-gp)\u2013mediated resistance is the usual cause of relapse in dogs with lymphoma. 1-(2-chloroethyl)3-cyclohexyl-1-nitrosurea (CCNU) and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) are alkylating agents that are not affected by P-gp and lack cross-resistance to each other. A combination protocol offers the advantage of improved summation dose and synergistic activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>A combination of CCNU and DTIC that is well tolerated can be used to treat dogs with lymphoma that developed resistance or failed to respond to previously administered chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-seven dogs with lymphoma that were resistant to treatment with standard chemotherapy (l-CHOP; l-asparaginase, cyclophosphamide, doxorubicin, vincristine, prednisone).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective phase I and II trials were performed. CCNU was given PO immediately before a 5-h IV infusion of DTIC. Concurrent antiemetics and prophylactic antibiotics were used. Treatments were administered every 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on the results of 8 dogs in the phase I study, CCNU at 40\u2003mg\/m2 PO combined with DTIC at 600\u2003mg\/m2 IV was used to treat 57 dogs with resistant lymphoma. Thirteen (23%) dogs had a complete response (CR) for a median of 83 days and 7 (12%) had a partial response for a median of 25 days. The median l-CHOP CR duration of the dogs that did not respond to CCNU-DTIC was significantly longer than that of the dogs that did achieve remission with CCNU-DTIC (225 days versus 92 days, P= .02). The principal toxic event was neutropenia; the median neutrophil count 7 days after treatment was 1,275\u2003cells\/\u03bcL. Increases in alanine transaminase activity, possibly associated with hepatotoxicity, were detected in 7 dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>A combination of CCNU and DTIC can be an effective option to rescue dogs with resistant lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2007.0005.x","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:41:44Z","timestamp":1229010104000},"page":"164-171","source":"Crossref","is-referenced-by-count":40,"title":["Combination of CCNU and DTIC Chemotherapy for Treatment of Resistant Lymphoma in Dogs"],"prefix":"10.1093","volume":"22","author":[{"given":"A.B.","family":"Flory","sequence":"first","affiliation":[{"name":"Cornell University Department of Clinical Sciences, College of Veterinary Medicine, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.M.","family":"Rassnick","sequence":"additional","affiliation":[{"name":"Cornell University Department of Clinical Sciences, College of Veterinary Medicine, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Al-Sarraf","sequence":"additional","affiliation":[{"name":"Animal Emergency and Referral Associates , Fairfield, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Long Island Veterinary Specialists , Plainview, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Balkman","sequence":"additional","affiliation":[{"name":"Cornell University Department of Clinical Sciences, College of Veterinary Medicine, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Kiselow","sequence":"additional","affiliation":[{"name":"Cornell University Department of Clinical Sciences, College of Veterinary Medicine, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Autio","sequence":"additional","affiliation":[{"name":"Cornell University Department of Clinical Sciences, College of Veterinary Medicine, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2026020304162105800_b1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b2","first-page":"948","article-title":"Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol","volume":"20","author":"Simon","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2460\/javma.1998.213.07.985","article-title":"Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma","volume":"213","author":"Khanna","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304162105800_b5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2000.tb02224.x","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"Chun","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5326\/15473317-36-5-395","article-title":"Treatment of canine lymphoma with COPLA\/LVP","volume":"36","author":"Boyce","year":"2000","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304162105800_b7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1939-1676.1997.tb00476.x","article-title":"Evaluation of a multidrug chemotherapy protocol (ACOPA-II) in dogs with lymphoma","volume":"11","author":"Myers","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/07357909509024910","article-title":"The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance","volume":"13","author":"Moore","year":"1995","journal-title":"Cancer Invest"},{"key":"2026020304162105800_b9","first-page":"354","article-title":"Monoclonal antibody C219 immunohistochemistry against P-glycoprotein","volume":"10","author":"Bergman","year":"1996","journal-title":"Sequential analysis and predictive ability in dogs with lymphoma"},{"key":"2026020304162105800_b10","first-page":"1892","article-title":"P-glycoprotein expression in canine lymphoma","volume":"77","author":"Lee","year":"1996","journal-title":"A relevant, intermediate model of multidrug resistance"},{"key":"2026020304162105800_b11","first-page":"374","volume-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","author":"Tew","year":"2001","edition":"3rd ed"},{"key":"2026020304162105800_b12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1939-1676.1999.tb01452.x","article-title":"Lomustine (CCNU) for the treatment of resistant lymphoma in dogs","volume":"13","author":"Moore","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-3164.1997.tb00262.x","article-title":"Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog","volume":"8","author":"Lemari\u00e9","year":"1997","journal-title":"Vet Dermatol"},{"key":"2026020304162105800_b14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2460\/javma.1984.184.07.814","article-title":"Histologic classification as an indicator of therapeutic response in malignant lymphoma in dogs","volume":"184","author":"Gray","year":"1984","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304162105800_b15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1939-1676.1990.tb00896.x","article-title":"Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine","volume":"4","author":"Van Vechten","year":"1990","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/jnci\/82.18.1469","article-title":"Selecting drug combinations based on total equivalent dose (dose intensity)","volume":"82","author":"Simon","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2026020304162105800_b17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.1993.11.4.794","article-title":"Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials","volume":"11","author":"Korn","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026020304162105800_b18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5810.2004.0053b.x","article-title":"Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","year":"2004","journal-title":"Vet Compar Oncol"},{"key":"2026020304162105800_b19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1939-1676.1999.tb02217.x","article-title":"Treatment of canine mast cell tumors with CCNU (lomustine)","volume":"13","author":"Rassnick","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b20","first-page":"1020","article-title":"Dacarbazine","volume":"22","author":"Fan","year":"2000","journal-title":"Comp Contin Ed"},{"key":"2026020304162105800_b21","first-page":"3876","article-title":"Treatment sequencing, asymmetry, and uncertainty","volume":"46","author":"Day","year":"1986","journal-title":"Protocol strategies for combination chemotherapy"},{"key":"2026020304162105800_b22","first-page":"2027","article-title":"The relationship between high-dose treatment and combination chemotherapy","volume":"4","author":"Frei","year":"1998","journal-title":"The concept of summation dose intensity"},{"key":"2026020304162105800_b23","first-page":"349","volume-title":"The Basic Science of Oncology","author":"Boyer","year":"2005","edition":"4th ed"},{"key":"2026020304162105800_b24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1476-5810.2006.00088.x","article-title":"Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma","volume":"4","author":"LeBlanc","year":"2006","journal-title":"Vet Compar Oncol"},{"key":"2026020304162105800_b25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1939-1676.2007.tb02938.x","article-title":"Combination chemotherapy with l-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma","volume":"21","author":"Saba","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b26","first-page":"173","article-title":"Detection and clinical significance of plasma glutathione-S-transferases in dogs with lymphoma","volume":"13","author":"Hahn","year":"1999","journal-title":"In Vivo"},{"key":"2026020304162105800_b27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1476-5810.2003.00027.x","article-title":"A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma","volume":"1","author":"Morrison-Collister","year":"2003","journal-title":"Vet Compar Oncol"},{"key":"2026020304162105800_b28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1939-1676.2006.tb02833.x","article-title":"CCNU in the treatment of canine epitheliotropic lymphoma","volume":"20","author":"Williams","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b29","first-page":"1389","article-title":"Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU)","volume":"20","author":"Risbon","year":"2006","journal-title":"A retrospective study of 46 cases (1999\u20132004)"},{"key":"2026020304162105800_b30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1939-1676.2004.tb00138.x","article-title":"Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs","volume":"18","author":"Kristal","year":"2004","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1939-1676.2003.tb02495.x","article-title":"Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides","volume":"17","author":"Trepanier","year":"2003","journal-title":"J Vet Intern Med"},{"key":"2026020304162105800_b32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2007.0005.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/1\/164\/66672073\/j.1939-1676.2007.0005.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/1\/164\/66672073\/j.1939-1676.2007.0005.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:16:58Z","timestamp":1770110218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/1\/164\/8449825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2007.0005.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,1]]},"published":{"date-parts":[[2008,1,1]]}}}